FOLH1 and breast carcinoma: Compared with the published 18F-FDG CLI results in breast cancer, the current protocol uses a 3 times lower activity and a 2 times shorter acquisition time which is possible due to the higher tracer uptake and Cerenkov yield of 68Ga-PSMA [18].